Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943477 | 0.90 | ADRB1 (0.45) | ALDH1A1KDM4EKCNH2MCHR1EGFR | |
| SCHEMBL2942087 | 0.89 | ALDH1A1 (0.46) | ALDH1A1EGFRLMNASMN1; SMN2ADRB1 | |
| SCHEMBL2949625 | 0.86 | BCL2L1 (0.46) | ALDH1A1KDM4EEGFRLMNAKMT2A | |
| SCHEMBL7676021 | 0.85 | ACHE (0.48) | KCNH2MCHR1EGFRADRB1ADRB3 | |
| SCHEMBL2943626 | 0.84 | CHEK1 (0.48) | ALDH1A1EGFRSMN1; SMN2ADRB1ADRB3 | |
| SCHEMBL2951136 | 0.80 | EGFR (0.49) | EGFRKMT2ASMN1; SMN2ADRB1ADRB3 | |
| SCHEMBL2952031 | 0.80 | EGFR (0.51) | KDM4EEGFRKMT2ASMN1; SMN2ADRB1 | |
| SCHEMBL2949557 | 0.79 | ADRB1 (0.48) | ALDH1A1KDM4EEGFRLMNAMEN1 | |
| SCHEMBL2947405 | 0.78 | CYP4A11 (0.55) | ALDH1A1EGFRKMT2ASMN1; SMN2ADRB1 | |
| SCHEMBL2951330 | 0.78 | EGFR (0.52) | ALDH1A1KDM4EEGFRKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ALDH1A1 2651/4885KDM4E 1911/4885KCNH2 3576/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ALDH1A1 2460/4885KDM4E 1563/4885KCNH2 3805/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | ALDH1A1 3404/4885KDM4E 1143/4885KCNH2 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.